(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, between June 21 st and 24 th, 2025, was host to the Barry Siegel Award Lecture ...
(UroToday.com) Prof Vittorio Canale presented his experience implementing and disseminating an ERAS program at his organization. Basic tenets need to be reinforced and audited. ERAS in Urology: A ...
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to stage and estimate risk for prostate cancer and a presentation by Dr. Derya Tilki discussing which patients need ...
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...
Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...
Thulium Fiber Laser Versus Holmium MOSES™ Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Prospective Clinical Study - Beyond the Abstract ...
Neeraj Agarwal speaks with Oliver Sartor and Daniel Petrylak about patient selection strategies for radioligand therapy. With multiple treatment options now available for metastatic ...
(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a radioligand and radionuclide therapy in advanced prostate cancer session and a presentation by Dr. Ken ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a metastatic urothelial carcinoma session and a presentation by Dr. Noritaka Ishii discussing real-world efficacy ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Alicia Morgans: I am going to be talking about incorporating PSMA PETs into registration trials with an example of a study that is relying on a PSMA PET endpoint as the primary endpoint in the study.
David Matheson discusses the patient perspective on radiographic progression-free survival as a clinical trial endpoint. Dr. Matheson argues that imaging-based progression is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results